SSA
VRTX icon

Schonfeld Strategic Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Schonfeld Strategic Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-20,000
Closed -$8.36M – 2592
2024
Q1 		$8.36M Buy
+20,000
New +$8.45M 0.06% 442

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Schonfeld Strategic Advisors's VRTX Position: Q2 2025 in Review

Schonfeld Strategic Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q2 2025, closing a stake of 2,400 shares — an estimated $1.16M sold.

Schonfeld Strategic Advisors first reported a position in VRTX in Q1 2016 and held it in 30 quarters. The position peaked at $32.9M in Q3 2024. 1,559 funds tracked by Wall St. Rank hold VRTX as of Q2 2025.

  • Schonfeld Strategic Advisors reported no remaining Vertex Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 2,400 Vertex Pharmaceuticals shares in Q2 2025, an estimated $1.16M.
  • Schonfeld Strategic Advisors first reported a position in Vertex Pharmaceuticals in Q1 2016 and held it in 30 quarters.
  • Schonfeld Strategic Advisors's Vertex Pharmaceuticals position peaked at $32.9M in Q3 2024.
  • 1,559 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.